Melanotan II: Molecular Characterization and Receptor Pharmacology — A Research Reference

The melanocortin peptides share a core motif of four residues — histidine, phenylalanine, arginine, tryptophan — that constitutes the receptor-engaging region of alpha-MSH and its relatives. Synthetic analogues in this family are generally built by constraining that motif rather than replacing it.

Melanotan II is constructed on exactly that principle. Written out, it is acetyl-norleucine followed by a ring closing between an aspartate and a lysine, enclosing histidine, D-phenylalanine, arginine, and tryptophan, with an amidated carboxyl terminus. Its molecular weight is approximately 1,024 daltons.

The ring is a lactam bridge: an amide bond formed between the side-chain carboxyl of the aspartate and the side-chain amine of the lysine. Quenched dynamics simulations were used to identify which cyclization would stabilize the conformation of interest, and the resulting lactam analogues proved substantially more potent and longer-acting in vitro than the linear parent [1, 2].

Two further modifications accompany the cyclization. Norleucine replaces methionine at the amino terminus, removing the sulphur-containing side chain that is the most oxidation-prone residue in the natural sequence. The phenylalanine is present in the D configuration rather than the L, which both alters the ring's preferred geometry and resists cleavage by proteases, which act on L-amino acid sequences.

The melanocortin receptor family comprises five class A G-protein-coupled receptors, designated MC1R through MC5R, which differ in tissue distribution and in their relative affinity for the natural and synthetic ligands of this class. They couple principally to Gαs; receptor activation stimulates adenylyl cyclase and raises intracellular cyclic AMP.

Melanotan II is characterized as a non-selective agonist across this family — engaging several of the five subtypes rather than discriminating sharply among them. That lack of selectivity is a property of the conserved core motif it retains, and it is precisely what subsequent medicinal chemistry sought to overcome: later work on cyclic melanotropin analogues systematically varied ring size, bridge chemistry, and residue substitutions to obtain subtype-selective compounds, using MT-II as the reference scaffold against which selectivity was measured [4].

For receptor-pharmacology work the molecule therefore serves two roles: as a conformationally constrained agonist in its own right, and as the parent scaffold from which a large family of selective analogues was derived.

Mass spectrometry confirms the intact molecular mass near 1,024 daltons. For a cyclic peptide the measurement carries additional information: cyclization eliminates a water molecule, so the ring-closed product is lighter than its linear precursor by a defined increment, and an observed mass matching the linear form indicates incomplete cyclization rather than a different sequence.

A second identity consideration is specific to this compound's catalogue neighbourhood. PT-141 shares the same cyclic core with a free acid in place of the C-terminal amide, separating the two molecules by roughly one dalton. Low-resolution mass spectrometry cannot reliably distinguish them, and a certificate reporting a rounded nominal mass does not settle which was supplied.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. The characteristic related substances are the uncyclized linear peptide and cyclic dimers, where the bridge formed between two chains rather than within one. Racemization at the D-phenylalanine position produces a diastereomer of identical mass that mass spectrometry cannot detect at all but that separates chromatographically — one of the clearer illustrations of why the two methods are run together.

Stability-indicating assay is unusually well characterized for this molecule: degradation kinetics in aqueous solution have been studied directly, establishing the pathways and conditions under which the cyclic lactam breaks down [3]. That work is the reference point for interpreting an unexpected impurity profile in a stored solution.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided. Published degradation kinetics indicate that aqueous stability is pH- and temperature-dependent, which is the mechanistic basis for the short working life of solutions relative to the lyophilized form [3].

Light protection matters more here than for many peptides because of the tryptophan residue, which is photosensitive and susceptible to oxidation. The substitution of norleucine for methionine removes the other major oxidation route, but tryptophan remains, and amber vials or foil wrapping during extended handling is standard practice for sequences containing it.

Cyclic peptides are otherwise well behaved once wet: the ring constrains conformational freedom, reducing the aggregation tendency that troubles long flexible chains, and the molecule dissolves readily without mechanical assistance.

Melanotan II is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade Melanotan II is accompanied by an independent certificate of analysis specific to that lot.

Melanotan II is a cyclic heptapeptide of approximately 1,024 daltons, closed by an aspartate-to-lysine lactam bridge identified through conformational simulation, carrying a norleucine substitution at the amino terminus and a D-configured phenylalanine within the ring. It is characterized as a non-selective agonist across the MC1R–MC5R family and serves as the reference scaffold for subsequent subtype-selective analogues. Analytical verification rests on mass confirmation of ring closure, chromatographic resolution of linear precursor, dimer, and diastereomer, and batch-specific net peptide content.